temsirolimus + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone

This is a multi-agent combination regimen consisting of six drugs: - Temsirolimus, an mTOR inhibitor and antineoplastic agent - Rituximab, a monoclonal antibody targeting CD20 on B lymphocytes - Cyclophosphamide, an alkylating agent - Doxorubicin, an anthracycline antibiotic with cytotoxic activity - Vincristine, a vinca alkaloid that inhibits microtubule formation - Prednisone, a synthetic glucocorticoid corticosteroid Each component has distinct mechanisms of action. Temsirolimus inhibits the mammalian target of rapamycin (mTOR), leading to cell cycle arrest and reduced tumor growth[1]. Rituximab binds to CD20 on B cells and mediates cell lysis through immune mechanisms[7]. Cyclophosphamide crosslinks DNA to prevent cell division. Doxorubicin intercalates into DNA and generates free radicals causing cytotoxicity. Vincristine disrupts mitotic spindle formation by binding tubulin. Prednisone exerts anti-inflammatory and immunosuppressive effects. This specific combination is not standard but represents an intensification or modification of established regimens for aggressive B-cell lymphomas such as diffuse large B-cell lymphoma (DLBCL). The closest standard regimen is R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)[2], with temsirolimus added as an investigational approach based on its activity in lymphoma when combined with other agents[4][8].

Brand names

ToriselRituxan

Other names

temsirolimus plus R-CHOPtemsirolimus with R-CHOPR-CHOP-T